Ted Lanpher

Ted co-founded Precedent in 2024 and serves as Executive Chairman. Earilier, he founded and led a startup that has developed an intranasal epinephrine product for treatment of anaphylaxis, which is currently in human trials. As a serial entrepeneur, he has led innovative respiratory technology companies in disease management, diagnostic instruments, and pharmaceuticals. BA Yale University, MBA. University of Virginia.